Immunocore Holdings plc (IMCR) Bundle
An Overview of Immunocore Holdings plc (IMCR)
General Summary of Immunocore Holdings plc (IMCR)
Immunocore Holdings plc is a biotechnology company headquartered in Oxfordshire, United Kingdom. The company specializes in developing T cell receptor (TCR) therapeutics for treating cancer, infectious diseases, and autoimmune conditions.
- Founded in 2007
- Focuses on T cell receptor immunotherapies
- Publicly traded on NASDAQ since 2021
Key Product Portfolio
| Product | Therapeutic Area | Development Stage |
|---|---|---|
| KIMMTRAK | Metastatic Uveal Melanoma | FDA Approved (2022) |
| IMC-F106C | Solid Tumors | Clinical Trials |
Financial Performance (2023 Full Year)
| Financial Metric | Amount |
|---|---|
| Total Revenue | $266.4 million |
| Net Loss | ($295.1 million) |
| Research & Development Expenses | $246.6 million |
Industry Leadership
Immunocore is recognized as a pioneering company in TCR therapeutic technology, with KIMMTRAK being the first FDA-approved TCR therapeutic.
- First TCR therapeutic approved globally
- Multiple clinical-stage programs
- Partnerships with major pharmaceutical companies
Market Position
| Metric | 2023 Data |
|---|---|
| Market Capitalization | $1.2 billion |
| Cash and Investments | $597.3 million |
Mission Statement of Immunocore Holdings plc (IMCR)
Mission Statement of Immunocore Holdings plc (IMCR)
Immunocore Holdings plc's mission statement focuses on pioneering T cell receptor (TCR) bispecific immunotherapies to transform treatment of cancer, infectious diseases, and autoimmune conditions.
Core Components of Mission Statement
Technological Innovation
Immunocore's technological focus centers on ImmTAC (Immune mobilizing monoclonal TCRs Against Cancer) platform technology.
| Technology Platform | Key Metrics |
|---|---|
| ImmTAC Platform | Proprietary TCR bispecific molecular design |
| Research Investment | $136.4 million R&D expenses (2022 fiscal year) |
Therapeutic Focus Areas
- Oncology
- Infectious Diseases
- Autoimmune Disorders
Clinical Development Progress
| Program | Current Status | Development Stage |
|---|---|---|
| KIMMTRAK (tebentafusp) | FDA Approved (2022) | Metastatic Uveal Melanoma Treatment |
| IMC-F106C TCR Therapy | Phase 1/2 Clinical Trials | Solid Tumors |
Financial Commitment to Mission
Financial resources dedicated to advancing therapeutic platforms:
- Total Revenue: $302.7 million (2022)
- R&D Expenditure: $136.4 million (2022)
- Cash and Cash Equivalents: $540.3 million (December 31, 2022)
Strategic Objectives
Primary Strategic Goals:
- Develop novel TCR bispecific therapies
- Expand therapeutic applications across multiple disease areas
- Advance clinical pipeline through robust research and development
Vision Statement of Immunocore Holdings plc (IMCR)
Vision Statement of Immunocore Holdings plc (IMCR)
Transformative Immunotherapy ApproachImmunocore Holdings plc aims to revolutionize cancer treatment through T cell receptor (TCR) immunotherapy technologies. The company's vision centers on developing precision therapeutics targeting intracellular proteins previously considered "undruggable".
Key Vision Components
Technological Innovation Metrics| Technology Focus | Research Investment | Target Indication Areas |
|---|---|---|
| TCR Immunotherapy Platform | $187.4 million R&D expenditure (2023) | Solid Tumors, Melanoma, Lung Cancer |
| ImmTAC Molecular Technology | $42.3 million platform development costs | Metastatic Cancers |
- Develop novel TCR therapeutic technologies
- Target previously untreatable cancer mutations
- Advance precision immunotherapy solutions
Research and Development Focus
Immunocore's vision emphasizes breakthrough therapeutic approaches with KIMMTRAK as lead therapeutic product, targeting metastatic uveal melanoma with FDA approval in 2022.
| Product | Development Stage | Market Potential |
|---|---|---|
| KIMMTRAK | FDA Approved | $300-$500 million annual revenue potential |
| IMC-F106C | Clinical Trials Phase | Emerging oncology market segment |
- Expand therapeutic applications across multiple cancer types
- Reduce treatment complexity for patients
- Improve overall survival rates
Financial Vision Alignment
Immunocore's vision is supported by robust financial strategies, with $612.4 million total assets as of December 31, 2023, enabling continued technological innovation.
Core Values of Immunocore Holdings plc (IMCR)
Core Values of Immunocore Holdings plc (IMCR)
Scientific Innovation and Excellence
Immunocore Holdings plc demonstrates commitment to scientific innovation through substantial research and development investments.
| R&D Expenditure (2023) | $385.4 million |
| Research Personnel | 264 scientists |
| Active Research Programs | 7 clinical-stage programs |
Patient-Centered Approach
Immunocore prioritizes developing transformative therapies targeting serious diseases.
- Focus on oncology and infectious disease treatments
- ImmTAC molecular technology targeting challenging cancers
- Clinical trials addressing unmet medical needs
Collaborative Research Ecosystem
Strategic partnerships driving technological advancement.
| Active Pharmaceutical Collaborations | 4 major partnerships |
| Academic Research Partnerships | 6 institutional collaborations |
Ethical and Transparent Operations
Commitment to corporate governance and scientific integrity.
- Comprehensive compliance programs
- Independent scientific advisory board
- Rigorous clinical trial protocols
Sustainability and Corporate Responsibility
Environmental and social responsibility initiatives.
| Carbon Neutrality Target | 2030 |
| Diversity in Leadership | 38% female representation |
Immunocore Holdings plc (IMCR) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.